Dr Ursula Ney joins the immunotherapies specialist with immediate effect, replacing Dr Matthew Frohn, who is standing down at the end of the month.
Ney was a director at UK biotech pioneers Celltech and Antisoma and spent her early career with Sandoz and Roche.
Most recently, she was chief executive of French drug developer Genkyotex and is currently a non-executive director of Proteome Sciences.
“Ursula’s extensive late-stage development experience in the biotech sector will be invaluable as the company continues to develop its product pipeline,” said Scancell chairman, Dr John Chiplin.
“I’d also like to take this opportunity to thank Matthew Frohn for the invaluable contributions he has made to the company since he was first appointed to the Board in 2006. We wish him well in his future endeavours.”